Biotech

Le 8 juilletJuly 2021) At the request of the company the common shares of Lexaria Bioscience Corp. will be delisted at market close on July 8, 2021.

The Company's common shares will continue to trade on NASDAQ Capital Markets ("Nasdaq")

For more details see the company press release.

_________________________________

À la demande de la société, les actions ordinaires de Lexaria Bioscience Corp. seront radiées à la clôture du marché le 8 juillet 2021.

Les actions ordinaires de la Société continueront d'être négociées sur le NASDAQ Capital Markets (« Nasdaq »)

Pour plus de détails, consultez le communiqué de presse de l'entreprise.

Date: Market Close/Clôture du marchés le 8 juillet/July 2021
Symbol(s)/Symbole(s): LXX

 

 

If you have any questions or require further information, please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

CHMP Adopts Positive Opinion Recommending Veklury® Receive Full Marketing Authorization for the Treatment of Patients With COVID-19

-- If Granted by the European Commission, Veklury will Become the Only Direct-Acting Antiviral with Full Marketing Authorization in the EU --

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Commission (EC) adopted a positive opinion on the fulfillment of the last specific obligation and recommended the granting of Marketing Authorization (MA) for Veklury ® (remdesivir) that is no longer subject to specific obligations. Veklury was initially granted a conditional marketing authorization in July 2020 for the treatment of COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at the start of treatment). In December of 2021, the conditional authorization was expanded to include adults who do not require supplemental oxygen and are at increased risk of developing severe COVID-19. The EC will review the CHMP recommendation and, pending adoption, Veklury will be fully authorized for these patients with COVID-19.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag for Treatment of Patients with Unresectable or Metastatic Melanoma

Approval recommended for first-line treatment of advanced melanoma patients with tumor cell PD-L1 expression

Recommendation based on results from the Phase 2/3 RELATIVITY-047 trial, in which the fixed-dose combination of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab more than doubled median progression-free survival compared to nivolumab monotherapy

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® for the Treatment of Adults with Active Lupus Nephritis in Europe

Positive CHMP opinion is based on a comprehensive submission including data from the pivotal AURORA 1 efficacy study and the AURORA 2 continuation study, demonstrating voclosporin to be safe and well tolerated for up to three years of treatment.

Based on the CHMP recommendation, a decision by the European Commission is expected in approximately two months.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic

Latest HIV Clinical Research and Development Data Drive the Next Wave of Innovation in Treatment, Prevention and Reaches Towards a Cure –

– Key Initiatives Highlight Role of Catalytic Collaboration to Help End the Epidemic for Everyone, Everywhere –

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry

Collaboration to kick off at "The Power of a Dream" National Convention in Orlando, Fla. to bridge professional diversity gaps to emphasize importance of health equity for communities of color

Bristol Myers Squibb NYSE (BMY) announced the first biopharma three-year exclusive collaboration with the premier African American Family Organization, Jack and Jill of America, Inc. to inspire more Black and African American individuals to join the biopharma industry to assist in creating more equity and better health outcomes for all patients through student engagement. The strategic alliance is an extension of BMS' Tomorrow's Innovators Historically Black College (HBCU ) initiative launched with the goal of creating a sustainable bridge of talent to the biopharma industry from the HBCU community and aligns with BMS's inclusion and diversity health equity commitments to increase workforce representation by creating and sustaining a pipeline of diverse talent.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Ankylosing Spondylitis

- Approval is supported by efficacy and safety data of two pivotal studies in which RINVOQ demonstrated improvements in disease activity and function 1
- Milestone marks the fourth Health Canada-approved indication for RINVOQ 2

  ABBVie (NYSE: ABBV), today announced that Health Canada has approved RINVOQ ® (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response to a biologic disease modifying anti-rheumatic drug (DMARD) or when use of those therapies is inadvisable. RINVOQ may be used as monotherapy or in combination with nonsteroidal anti-inflammatory drugs (NSAIDS). 2

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×